Mycenax Biotech Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was TWD 151.6 million compared to TWD 106.73 million a year ago. Net loss was TWD 116.43 million compared to TWD 69.1 million a year ago. Basic loss per share from continuing operations was TWD 0.76 compared to TWD 0.45 a year ago. Diluted loss per share from continuing operations was TWD 0.76 compared to TWD 0.45 a year ago.
For the six months, sales was TWD 377.15 million compared to TWD 398.95 million a year ago. Net loss was TWD 98.12 million compared to net income of TWD 45.28 million a year ago. Basic loss per share from continuing operations was TWD 0.64 compared to basic earnings per share from continuing operations of TWD 0.32 a year ago. Diluted loss per share from continuing operations was TWD 0.64 compared to diluted earnings per share from continuing operations of TWD 0.31 a year ago.